li001

New results from a phase 1 trial (NCT05507827) show that combining Orca-T with donor-derived (allogeneic) CAR T-cell therapy may be a safe and highly effective treatment for high-risk B-cell acute lymphoblastic leukemia (B-ALL). Traditional CAR T therapy often does not produce long-lasting remissions and is frequently used as a bridge to transplant. Orca-T is a […]

Researchers have shown that a genetically modified virus can help the immune system attack glioblastoma, one of the most aggressive brain cancers. The study was published in Cell. Glioblastoma is usually resistant to immunotherapy because it is considered an “immune cold” tumor, meaning immune cells do not easily enter or attack it. In this study,

Treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC) has moved beyond a single standard approach. In the past, most patients received osimertinib alone. Now, doctors choose between single-drug therapy and stronger combination treatments based on the patient’s condition and cancer behavior. Osimertinib (brand name Tagrisso) remains an important option, especially for patients with lower-risk

Researchers have identified a potential new treatment approach for Epstein-Barr virus–positive (EBV+) gastric cancer, a subtype marked by extreme DNA hypermethylation that shuts down tumor-suppressor genes. In this cancer type, the virus triggers a process called CpG Island Methylator Phenotype (CIMP). This adds methyl groups to DNA, acting like an “off switch” that silences genes

Long-term results from the phase 2 M20-075 study show that the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) provides strong and lasting responses in patients with relapsed or refractory mantle cell lymphoma (MCL). After a median follow-up of 37.2 months, the overall response rate was 83.3%. Among patients who could be evaluated, 83% achieved a

A new study suggests that high-dose palliative radiation therapy can be an effective and tolerable option for patients with incurable mucosal head and neck squamous cell carcinoma (HNSCC) who are not candidates for standard chemoradiotherapy. In the study, 92.4% of patients completed the full radiation course of 50–55 Gy delivered over four weeks. At 12